| Accession number;05A0356958 |
| Title;Appropriate Glimepiride Dosage When Switching from Glibenclamide/Gliclazide in Type 2 Diabetes in a Japanese Population |
| Author;MATSUHIRA TOORU(Jikei Univ. School of Medicine) AKUTSU TOSHIE(Jikei Univ. Aoto Hosp.) SOMEYA YASUHISA(Jikei Univ. Daisan Hosp.) AIHARA KAZUO(Tokyu Corp. Tokyu Hosp.) YOSHIZAWA SHOKO(Machida City Hospital, JPN) YAMAZAKI HIROYUKI(Kawaguchi Municipal Medical Center, JPN) NARIMIYA MANABU(Nishi Saitama Chuo National Hospital, JPN) AGATA TOSHIHIKO(Fac. Medicine, Jikei Univ. School of Medicine, JPN) SAKAMOTO YOICHI(Jikei Univ. School of Medicine) |
Journal Title;Journal of the Japan Diabetic Society
|
Journal Code:Z0279B
|
ISSN:0021-437X
|
|
VOL.48;NO.3;PAGE.159-164(2005)
|
| Figure&Table&Reference;FIG.1, TBL.3, REF.9 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Appropriate glimepiride dosage when switching from widely used sulfonylureas (SU) to glimepiride is not well documented, so we studied the glimepiride dosage and change in HbA1c among type 2 diabetic patients who were on glibenclamide (2.5-5.0 mg) or gliclazide (40-80 mg). We stratified patients into 4 groups based on previous regimens and set the glimepiride dosage as follows: group A: glibenclamide 2.5 mg to glimepiride 2 mg daily; group B: glibenclamide 5.0 mg to glimepiride 3 or 4 mg daily; group C: gliclazide 40 mg to glimepiride 1 mg daily; group D: gliclazide 80 mg to glimepiride 2 mg daily. Clinical data were examined before and after 6 months of observation. The glimepiride dosage was adjusted by physicians. Glimepiride dosages were increased in all groups, and significantly so in groups B and C. We concluded that the initial dosage of glimepiride to be substituted for previously used SU to maintain similar HbA1c may not be enough. (author abst.) |
